ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Anbio Biotechnology's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was 29.59%.
As of today (2026-07-04), Anbio Biotechnology's WACC % is 9.05%. Anbio Biotechnology's ROC % is 45.68% (calculated using TTM income statement data).
Anbio Biotechnology generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Anbio Biotechnology (NAS:NNNN) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Anbio Biotechnology's WACC % is 9.05%. Anbio Biotechnology's ROC % is 45.68% (calculated using TTM income statement data).
Anbio Biotechnology generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Anbio Biotechnology ROC % Related Terms
Anbio Biotechnology ROC % Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's ROC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is two times the semi-annual (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a ROC % of 29.59% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Anbio Biotechnology and its competitors.
Is Anbio Biotechnology's ROC % too high?
Anbio Biotechnology's current ROC % is 29.59%. The Medical Devices & Instruments industry median ROC % is 1.26. Anbio Biotechnology's value of 29.59% is 2257.8% above this industry median. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's ROC % compare to ANGO and OSUR?
Anbio Biotechnology's ROC % of 29.59% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.26. Anbio Biotechnology's value of 29.59% is 2257.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Devices & Instruments company?
The median ROC % among Medical Devices & Instruments companies is 1.26, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current ROC % of 29.59% is 2257.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current ROC % is 29.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current ROC % of 29.59%. The current ROC % is 29.59% and 2257.8% above the Medical Devices & Instruments industry median of 1.26. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current ROC % is 29.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
